Sanofi (SNY)


NYSE - NYSE Real Time Price. Currency in USD
38.04-0.31 (-0.81%)
At close: 4:02 PM EDT

38.04 0.00 (0.00%)
After hours: 4:19 PM EDT

People also watch:
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open38.11
Prev Close38.35
Bid38.07 x 2500
Ask38.08 x 900
Day's Range37.92 - 38.15
52wk Range37.41 - 51.88
1y Target EstN/A
Market Cap97.92B
P/E Ratio (ttm)21.22
Beta0.90
Volume1,556,168
Avg Vol (3m)2,454,938
Dividend & Yield1.66 (4.34%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Regeneron, Sanofi Skin Disease Drug Under Priority Review
    Zacks2 hours ago

    Regeneron, Sanofi Skin Disease Drug Under Priority Review

    Regeneron (REGN) and partner Sanofi's atopic dermatitis treatment, dupilumab, is under priority review in the U.S. A response should be out by Mar 29, 2017.

  • Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema
    Investor's Business Daily58 minutes ago

    Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema

    The FDA could approve a breakthrough adult eczema treatment from Regeneron and Sanofi as soon as March.

  • Reuters4 hours ago

    Sanofi gets $43 mln U.S. funding to spur Zika vaccine development

    Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum. The funding from the HHS' Biomedical Advanced Research and Development Authority (BARDA) will be used for mid-stage trials, expected to begin in the first half of 2018, and for manufacturing, the French drugmaker said. Work on the vaccine began in March as a collaborative effort between the U.S. Department Of Defense's Walter Reed Army Institute of Research (WRAIR), BARDA and the National Institutes of Health.